Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Johnson & Johnson/IsoStent

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson/IsoStent: J&J's Cordis unit bolsters its coronary stent pipeline through the acquisition of the BX Stent from privately held IsoStent. Currently in development, the BX utilizes a "slotted tube" design to provide "greater flexibility" during implantation and "superior radial strength following deployment," J&J maintains. The device, for which J&J previously had obtained an option for international marketing rights, is intended for use in saphenous vein grafts as well as "normal stenting procedures." Also acquired is development-stage technology for catheter-based intravascular radiation therapy to help prevent restenosis. J&J and Belmont, California-based IsoStent will continue to collaborate under a March 1996 agreement to develop radioactive versions of J&J's Palmaz-Schatz coronary stent ("The Gray Sheet" April 22, 1996, I&W-1)...
Advertisement

Related Content

Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Advertisement
UsernamePublicRestriction

Register

MT009593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel